Zebrafish-Based Drug Discovery and Pharmacophenomics

Here, we propose the strategy of zebrafish-based quantitative and systems ph
armacology, which synergistically combine the desirable features of systems
pharmacology and emerging technology of zebrafish-based phenotype screening system for functional omics and chemical biology.
Zebrafish-based systems pharmacology that analyze in vivo regulatory
networks involved in drug action can account for a drug's multiple targets
and for the effects of genomic, epigenomic, and posttranslational changes on
 the drug efficacy. The next generation discipline of systems pharmacology
aims to combine experimental analysis and computational modeling of in vivo networks with quantitative pharmacology approaches to drive the drug discovery processes, predict rare adverse events, and catalyze the practice of personalized medicine.
This new systems pharmacology can drive zebrafish-based drug discovery and shape personalized medicine.
It was found that 56% of first-in-class approvals had come from phenotypic screens, 34% had come from target-based approaches (Nat. Rev. Drug Discov. 10, 507–519; 2011).The zebrafish has become a prominent vertebrate model for disease and has already contributed to several examples of successful phenotype-based drug discovery. For the zebrafish to become useful in drug development more broadly, key hurdles must be overcome, including a more comprehensive elucidation of the similarities and differences between human and zebrafish biology.
It is hoped that the zebrafish will have a key role in accelerating the emergence of pharmacophenomics-driven drug discovery.

Wednesday, 13 September

Session III: Biomolecules and Drug Design
Chair: Ted Hupp (UK)

09:00 – 09:20 Amino acid hydroxylation, a common and sometimes misunderstood post-translational modification
Dr Alex Kreigsheim (UK)

09:20 – 09:40 Marine natural resources in drug discovery and development: Case from Mauritian waters
Dr Vidushi Neergheen-Bhujun (Mauritus)

09:40 – 10:00 Dr Alexis Ivanov (Russia)

10:00 – 10:20 Inhibition of prokaryotic ribosomes by antibiotics: structure and functional studies
Dr Andrei Konevega (Russia)

10:20 – 10:40 The Odyssey that is Invadolysin: from “ugly chromosomes” to serum protease
Prof Margarete Heck (UK)

10:40 – 11:00 Prof Andrei Gilep (Belarus)

11:00 – 11:20 NGS-based molecular profiling of solid tumors and targeted cancer therapy
Dr Anton Tikhonov (Russia)

11:20 – 11:40 Prof Valentin Stonik (Russia)

11:40 – 12:00 Zebrafish-Based Drug Discovery and Pharmacophenomics
Prof Toshio Tanaka (Japan)


Future of Biomedicine 2017 Conference